Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male, non-smoker, 21-75 years of age~* female, non-smoker, 40-75 years of age~* post-menopausal women, as defined by lack of menses for at least 2 years and age \>55, OR history of documented bilateral oophorectomy, confirmed with an elevated FSH at screening~* low-density lipoprotein (LDL) concentration between 130-200 mg/dL.~* triglyceride (TG) concentration \<350 mg/dL, inclusive~* high-density lipoprotein (HDL) between 30-60 mg/dL for men and 40 -70 mg/dL for women~* ability to give informed consent~Exclusion Criteria:~* Subject has history of diabetes mellitus, active hepatitis, gall bladder disease, gastric or ileal bypass surgery, irritable bowel syndrome, and gastrointestinal disorder/condition associated with malabsorption, or clinically significant abnormalities on screening (prestudy) physical examination of laboratory tests.~* Screening laboratory tests with hematocrit \<30%, aspartate aminotransferase/alanine aminotransferase (AST/ALT) \>2\*upper limit of normal, abnormal thyroid-stimulating hormone (TSH), fasting glucose \>=126mg/dL~* renal impairment with creatinine clearance (CRCl)\<80ml/min~* treatment within the last 2 months with drugs known to alter lipid metabolism including beta blockers, thiazide diuretics, bile acid resins, statins, ezetimibe, niacin, fibrates, plant stanol esters (eg Benecol,phyto sterols) and fishoils~* history of known coronary heart disease (CHD), stroke or prior revascularization procedure or peripheral vascular disease~* history of allergy to egg or soy products~* current or recent (past 12 months) of drug abuse or alcohol abuse. Alcohol use must be limited to no more than 2 drinks/day (1 drink=12 oz beer, 5 oz wine, or 1.5 oz hard liquor). Subject must be willing to avoid large day-to-day fluctuations in alcohol intake.~* participation in another clinical trial or exposure to any investigational agent within 30 days prior to Visit 1~* Individual has a condition the Principal Investigator believes would interfere with his/her ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results, or put the subject at undue risk

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): ezetimibe (10mg/day)for 7 weeks
- 2 (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).